Unlabelled: The process of interpreting and acting upon the visual environment requires both intact cognitive and visual systems. The narrative description (ND) task, initially developed to detect changes in ecologically relevant visual function in people with impaired vision, is an objective measure of the ability to perceive, understand, and describe a visual scene in a movie clip.
Objective: Because the ND task draws heavily on semantic and working memory ability in addition to basic visual perception, we aimed to assess the discriminative performance of this task across levels of cognitive impairment.
Method: We recruited 56 participants with cognitive status ranging from normal cognition to mild dementia (median age 82, range 66 to 99 years) to watch 20 30-s video clips and describe the visual content without time constraints. These verbal responses were transcribed and processed to generate ND shared word scores using a "wisdom of the crowd," natural-language processing approach. We compared ND scores across diagnostic groups, and used linear mixed models to examine decrements in task performance.
Results: There was a stepwise decline of ND scores with increasing levels of cognitive impairment. Additional analyses showed that ND performance was highly related to performance on the Montreal Cognitive Assessment (MoCA) and domain-specific neuropsychological tests for semantic fluency and set shifting. Other models demonstrated differences in ND performance related video content between cognitively normal and impaired participants.
Conclusion: The ND test was able to detect decrements in task performance between levels of cognitive impairment and was related to other global neuropsychological measures. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182468 | PMC |
| http://dx.doi.org/10.1037/neu0000621 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differences of longitudinal plasma biomarkers between single memory domain and multidomain subject cognitive decline: Evidence from SILCODE.
J Alzheimers Dis
January 2025
Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
Background: Plasma biomarkers demonstrated potential in identifying amyloid pathology in early Alzheimer's disease. Different subtypes of subjective cognitive decline (SCD) may lead to different cognitive impairment conversion risks.
Objective: To investigate the differences of plasma biomarkers in SCD subtypes individuals, which were unclear.
Development and evaluation of a free e-learning program on dementia risk reduction for the general public: A pre-post study.
J Alzheimers Dis
January 2025
Alzheimer Centrum Limburg, Mental Health and Neuroscience Research Institute (MHeNs), Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, Netherlands.
Background: There is consistent evidence for the contribution of modifiable risk factors to dementia risk, offering opportunities for primary prevention. Yet, most individuals are unaware of these opportunities.
Objective: To investigate whether online education about dementia risk reduction may be a low-level means to increase knowledge and support self-management of modifiable dementia risk factors.
Urinary formic acid is associated with cerebral amyloid deposition and glucose metabolism in memory clinic patients.
J Alzheimers Dis
January 2025
Department of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Urinary formic acid (FA) has been reported to be a biomarker for Alzheimer's disease (AD). However, the association between FA and pathological changes in memory clinic patients is currently unclear.
Objective: This study aims to investigate associations between FA and pathological changes across different cognitive statuses in memory clinic patients.
SMOC2 promotes microglia activity and neuroinflammation in Alzheimer's disease.
J Alzheimers Dis
January 2025
Department of Vascular Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: Alzheimer's disease (AD), the leading cause of dementia, is characterized by cognitive decline and the accumulation of amyloid-β (Aβ). It affects millions, with numbers expected to double by 2050. SMOC2, implicated in inflammation and fibrosis, may play a role in AD pathogenesis, particularly in microglial cell function, offering a potential therapeutic target.
View Article and Find Full Text PDFAnti-neuroinflammatory and Neuroprotective Effects of T-006 on Alzheimer's Disease Models by Modulating TLR4-Mediated MyD88/ NF-κB Signaling.
CNS Neurol Disord Drug Targets
January 2025
School of Medicine, Foshan University, Foshan, 528000, China.
Introduction: Neuroinflammation derived from the activation of the microglia is considered a vital pathogenic factor of Alzheimer's Disease (AD). T-006, a tetramethylpyrazine derivative, has been found to alleviate cognitive deficits via inhibiting tau expression and phosphorylation in AD transgenic mouse models. Recently, T-006 has been proven to dramatically decrease the levels of total Amyloid β (Aβ) peptide and Glial Fibrillary Acidic Protein (GFAP) and suppress the expression of ionized calcium binding adaptor molecule-1 (Iba-1) in APP/PS1 mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!